{"transactions":[{"id":3296915,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":3,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2020-01-31T21:55:52.000Z","date":"2020-01-29","kind":"exercise","acquired":false,"shares":19500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,136,400 shares of Common Stock held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"), 170,460 shares of Common Stock held of record by OrbiMed Partners Master Fund Limited (\"OPM\") and 170,460 shares of Common Stock held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"), as adjusted for the Reverse Split. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors is the managing member of GP VII. OrbiMed Global Healthcare GP LLC (\"Healthcare GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Healthcare GP. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment manager of OPM and OrbiMed Capital is a relying advisor of OrbiMed Advisors. (Continued in footnote 4)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VII and as a result may be deemed to have beneficial ownership of such securities; Healthcare GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities; and OrbiMed Capital may be deemed to have voting power and investment power over the securities held by OPM and as a result, may be deemed to have beneficial ownership over such securities. Each of GP VII, Healthcare GP, OrbiMed Advisors and OrbiMed Capital disclaims beneficial ownership of the shares held by OPI VII, Genesis or OPM, as applicable, except to the extent of its or her pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Consists of 19,500 shares of Series A Preferred Stock which are convertible into an aggregate of 1,477,320 shares of Common Stock, as adjusted for the Reverse Split. Of the shares reported, 15,000 shares of Series A Preferred Stock are held of record by OPI VII, 2,250 shares of Series A Preferred Stock are held of record by Genesis, and 2,250 shares of Series A Preferred Stock are held of record by OPM."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1477320},"source":{"system":"sec-edgar","filing":"0001209191-20-005791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120005791/doc4.xml","form_type":"4"}},{"id":3296914,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":3,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":4,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-31T21:55:52.000Z","date":"2020-01-29","kind":"exercise","acquired":true,"shares":1477320,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Convertible Voting Preferred Stock (the \"Series A Preferred Stock\") converted into 75.76 shares of the Issuer's Common Stock, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019.  The Series A Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the \"Reverse Split\") was effected. These securities reflect the Reverse Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of 1,136,400 shares of Common Stock held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"), 170,460 shares of Common Stock held of record by OrbiMed Partners Master Fund Limited (\"OPM\") and 170,460 shares of Common Stock held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"), as adjusted for the Reverse Split. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors is the managing member of GP VII. OrbiMed Global Healthcare GP LLC (\"Healthcare GP\") is the general partner of Genesis and OrbiMed Advisors is the managing member of Healthcare GP. OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment manager of OPM and OrbiMed Capital is a relying advisor of OrbiMed Advisors. (Continued in footnote 4)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"GP VII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VII and as a result may be deemed to have beneficial ownership of such securities; Healthcare GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities; and OrbiMed Capital may be deemed to have voting power and investment power over the securities held by OPM and as a result, may be deemed to have beneficial ownership over such securities. Each of GP VII, Healthcare GP, OrbiMed Advisors and OrbiMed Capital disclaims beneficial ownership of the shares held by OPI VII, Genesis or OPM, as applicable, except to the extent of its or her pecuniary interest therein, if any."}],"balance_after":1477320,"source":{"system":"sec-edgar","filing":"0001209191-20-005791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919120005791/doc4.xml","form_type":"4"}},{"id":3862310,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":2,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2018-07-24T20:46:59.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":3500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VI, LP. OrbiMed Capital GP VI LLC is the sole general partner of OrbiMed Private Investments VI, LP, and OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VI LLC. By virtue of such relationships, OrbiMed Capital GP VI LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Private Investments VI, LP and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Capital GP VI LLC, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317921},"source":{"system":"sec-edgar","filing":"0000899243-18-020515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924318020515/doc4.xml","form_type":"4"}},{"id":3862309,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":2,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2018-07-24T20:46:59.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":3500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by OrbiMed Global Healthcare Master Fund, L.P. OrbiMed Global Healthcare GP LLC is the sole general partner of OrbiMed Global Healthcare Master Fund, L.P., and OrbiMed Advisors LLC is the managing member of OrbiMed Global Healthcare GP LLC. By virtue of such relationships, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Global Healthcare Master Fund, L.P. and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Capital GP VI LLC, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317921},"source":{"system":"sec-edgar","filing":"0000899243-18-020515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924318020515/doc4.xml","form_type":"4"}},{"id":3862308,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":2,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-24T20:46:59.000Z","date":"2018-07-23","kind":"purchase","acquired":true,"shares":100000,"price":15,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VI, LP. OrbiMed Capital GP VI LLC is the sole general partner of OrbiMed Private Investments VI, LP, and OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VI LLC. By virtue of such relationships, OrbiMed Capital GP VI LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Private Investments VI, LP and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Capital GP VI LLC, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":417921,"source":{"system":"sec-edgar","filing":"0000899243-18-020515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924318020515/doc4.xml","form_type":"4"}},{"id":3862307,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":2,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-24T20:46:59.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":317921,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VI, LP. OrbiMed Capital GP VI LLC is the sole general partner of OrbiMed Private Investments VI, LP, and OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VI LLC. By virtue of such relationships, OrbiMed Capital GP VI LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Private Investments VI, LP and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Capital GP VI LLC, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":317921,"source":{"system":"sec-edgar","filing":"0000899243-18-020515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924318020515/doc4.xml","form_type":"4"}},{"id":3862306,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":2,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-24T20:46:59.000Z","date":"2018-07-23","kind":"purchase","acquired":true,"shares":100000,"price":15,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by OrbiMed Global Healthcare Master Fund, L.P. OrbiMed Global Healthcare GP LLC is the sole general partner of OrbiMed Global Healthcare Master Fund, L.P., and OrbiMed Advisors LLC is the managing member of OrbiMed Global Healthcare GP LLC. By virtue of such relationships, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Global Healthcare Master Fund, L.P. and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Capital GP VI LLC, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":417921,"source":{"system":"sec-edgar","filing":"0000899243-18-020515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924318020515/doc4.xml","form_type":"4"}},{"id":3862305,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152106,"kind":"person","name":"OrbiMed Global Healthcare GP LLC","position":2,"cik":"0001673892","reported_name":"OrbiMed Global Healthcare GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-24T20:46:59.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":317921,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 23, 2018, the Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are held of record by OrbiMed Global Healthcare Master Fund, L.P. OrbiMed Global Healthcare GP LLC is the sole general partner of OrbiMed Global Healthcare Master Fund, L.P., and OrbiMed Advisors LLC is the managing member of OrbiMed Global Healthcare GP LLC. By virtue of such relationships, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC may be deemed to have voting and investment power over the securities held by OrbiMed Global Healthcare Master Fund, L.P. and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Capital GP VI LLC, OrbiMed Global Healthcare GP LLC and OrbiMed Advisors LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":317921,"source":{"system":"sec-edgar","filing":"0000899243-18-020515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000089924318020515/doc4.xml","form_type":"4"}}]}